13th International Conference on Myasthenia Gravis and Related Disorders

第十三届重症肌无力及相关疾病国际会议

基本信息

批准号：
9331903
负责人：
Melanie Brickman Borchard
金额：
$ 1.5万
依托单位：
NEW YORK ACADEMY OF SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-05-15 至 2018-05-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9331903
关键词：
Academia Academy Address Advocate Americas Animal Model Area Autoimmune Diseases Autoimmune Process Autoimmunity Award Basic Science Caring Case Study Child Chronic Disease Clinic Clinical Clinical Investigator Clinical Trials Collaborations Communication Communities Congresses Data Development Diagnosis Disabled Persons Disease Educational workshop Emerging Technologies Etiology Event Faculty Family Fatigue Fellowship Female Fostering Foundations Future Genomics Goals Government Guidelines Health Immunotherapy Industry International Internet Knowledge Life Expectancy Medical Mentors Minority Mission Modernization Muscle Weakness Myasthenia Myasthenia Gravis National Institute of Neurological Disorders and Stroke Neurobiology Neurologic Neuromuscular Diseases Neuromuscular Junction New York New York City Nicotinic Receptors Oral Participant Pathogenesis Patient Care Patient-Focused Outcomes Patients Pharmacologic Substance Phenotype Physicians Physiological Prize Process Public Health Publications Publishing Quality of life Research Research Personnel Science Scientist Serological Structure Syndrome Techniques Technology Therapeutic Translating Translations Travel Treatment Protocols Underrepresented Minority Update Woman aging population career clinical care clinical development disability discount improved innovation meetings minority investigator mortality multidisciplinary nervous system disorder neuromuscular neuromuscular function posters programs racial and ethnic racial minority receptor structure function repository research and development response screening standard care symposium treatment response

项目摘要

13th International Conference on Myasthenia Gravis and Related Disorders PROJECT SUMMARY / ABSTRACT The treatment for myasthenia gravis (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. However, many knowledge gaps still remain to improving MG patient outcomes including the understanding the origin of MG, identifying the factors that contribute to chronic disease, and finding a way to cure the disease. To address these unmet needs, the New York Academy of Sciences and the Myasthenia Gravis Foundation of America will convene the 3-day 13th International Conference on Myasthenia Gravis and Related Disorders on May 15 – 17, 2017, in New York City, NY. This conference will convene approximately 300 attendees — including basic scientists and clinical investigators in academia, industry, and government; physicians; pharmaceutical strategists; and patient advocates — in an effort to address these aforementioned knowledge gaps. Conference sessions will combine basic, translational, and clinical researchers and will feature a unique format of short, focused talks centered on critical open research questions, with the 13 plenary sessions focusing on: structure and function of the neuromuscular junction, congenital syndromes, serological phenotypes, mechanisms of autoimmunity, recent clinical developments, animal models of neuromuscular disease, MG treatment updates, and global MG treatment guidelines. The five central aims of this program are to: (i) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; (ii) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; (iii) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; (iv) identify knowledge gaps and future directions of research required for further breakthroughs; and (v) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration. The conference goals align well with the mission of the National Institute of Neurological Disorders and Stroke (NINDS) to support the advancement of new knowledge on neurological disorders. In addition, the NINDS’ specific goal of disseminating information about scientific discoveries and their implications for neurological health will be met via a live simulcast broadcast of the meeting and the publication of a post-conference, enduring, open-access, Section 508-compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the meeting to the global research and medical communities. Only through cross-field collaborative research envisioned as a result of this conference can we fully guide research forward in the field, particularly with respect to potential innovative therapeutic approaches.

第13届肌无力及相关疾病国际会议项目摘要 /摘要肌无力重症疗法（MG） - 一种罕见的，获得的自身免疫性综合征，导致严重的肌肉弱点，严重的残疾和预期寿命增加 - 在过去的几个几十年。但是，许多知识差距仍然存在，以改善MG患者预后了解MG的起源，确定导致慢性疾病的因素，并发现治愈疾病的方法。为了满足这些未满足的需求，纽约科学院和美国肌无力的疗法基金会将召集为期3天的第13届国际会议 2017年5月15日至17日在纽约州纽约市，肌无力及相关疾病。这次会议将召集大约300名与会者 - 包括学术界的基础科学家和临床研究人员，工业和政府；医师；药物策略；和患者的拥护者 - 努力解决这些合理的知识差距。会议将结合基本，翻译和临床研究人员将采用以关键开放研究为中心的简短，专注的演讲的独特格式问题，13个全体会议的重点是：神经肌肉连接的结构和功能，先天性综合征，血清学表型，自身免疫机制，近期临床发展，神经肌肉疾病的动物模型，MG治疗更新和全球MG 治疗指南。该计划的五个核心目的是：（i）为基本，翻译，以及来自学术界和行业的临床研究人员，介绍和讨论最新的发现 MG研究；（ii）探索和鼓励多学科和多部门合作以增强调查方法对MG和相关的自身免疫性和神经肌肉疾病；（iii）审查当前MG 治疗选择，正在进行的临床试验以及诊所面临的挑战和局限性；（iv）识别知识差距和未来的研究方向，需要进一步突破；（v）展示柜和鼓励参与早期职业，女性和代表性不足的少数族裔调查员会谈，海报演示，旅行奖学金，职业指导活动和折扣注册。会议目标与国家神经系统疾病与中风研究所（NINDS）的使命非常吻合支持有关神经系统疾病的新知识的发展。此外，Ninds的具体目标传播有关科学发现及其对神经健康的影响的信息将得到满足通过现场模拟广播，会议和会议后，持久，开放式访问的出版纽约科学院纪事中的第508条会议报告，该报告将分发会议上与全球研究和医学界交流的科学知识和思想。只有通过跨场协作研究，我们会议的结果才能完全指导该领域的研究，特别是在潜在的创新治疗方法方面。